A comparison of an enzyme-linked immunosorbent assay and counter current electrophoresis for the detection of bovine serum albumin in virus vaccines. by Avest, A.R. (Anja) ter et al.
Journal of Biological Standardization (1987) IS, 245-250 
A comparison of an enzyme-linked 
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Albert D. M. E. Osterhazls”f 
A monoclonai antibody directed against bovine serum albumin (BSA) has been developed and 
used in an enzyme-linked immunosorbent assay (ELISA) system for the detection of BSA in virus 
vaccines. The results correlated well with those obtained with a counter current electrophoresis 
system which has been employed routinely for this purpose. The ELISA was slightly more 
sensitive and more readily applicable to the screening of large numbers of samples but could not 
be used in the presence of certain stabilizers. 
INTRODUCTION 
The production of many virus vaccines in cell culture is still dependent on the presence 
of bovine serum in the cell-culture medium. In order to avoid unwanted side effects 
after vaccination, the presence of non-relevant proteins in virus vaccines, including 
bovine serum proteins, should be kept to a minimum. According to WHO require- 
ments the amount of bovine serum protein in human vaccines should not exceed 60 ng 
ml-’ of vaccine. i As bovine serum albumin (BSA) is the major protein present in 
bovine serum, the total amount of bovine serum proteins may be estimated by 
determining the BSA content by counter current electrophoresis (CCE) using a rabbit 
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antiserum directed against BSA.* However, this method is time consuming and hardly 
applicable to large numbers of samples. Recently Edevag et ai. described the 
development of an enzyme-linked immunosorbent assay (ELISA) for ovalbumin 
determination in influenza vaccines produced in hens’ eggs.3 We have developed an 
ELISA which determines BSA content on the basis of the reactivity of the BSA with an 
anti-BSA monoclonal antibody. A comparison of the results obtained in ELISA and 
CCE with a series of candidate human and veterinary virus vaccines showed that they 
coincided well and that ELISA was both more sensitive and more readily applicable to 
the screening of large numbers of samples. However, the ELISA could not be used for 
vaccines to which stabilizers, for instance a high concentration of human serum 
albumin (HSA), has been added. 
MATERIALS AND METHODS 
Generation of hybridonus 
Lymphocytes were obtained from the spleens of two BALB/c mice which had been 
immunized intramuscularly with 0.5 mg of BSA in 0.25 ml of saline (Boseral, 
Organon, Oss, The Netherlands) emulsified with an equal volume of Freund’s 
complete adjuvant (Difco Laboratories Inc., Detroit, MI). Immunized mice were 
boosted six weeks later with 0.1 mg of BSA in 0.1 ml ofsaline intravenously, 4,3 and 2 
days before fusion. Hybridization and cultivation were carried out essentially as 
described by Kohler and Milstein4 with minor modifications.5 
Screening of hybrid cells 
Hybridomas were screened for the production of anti-BSA antibodies by immune 
fluorescence (IF). For this purpose BSA (fraction V, Calbiochem, San Diego, CA) was 
labelled with fluorescein-isothiocyanate (FITC) (Isomer I, BBL Microbiological Sys- 
tems) according to a standard procedure.’ About 100-200 of the hybrid cells from 
each well were collected and washed three times with phosphate buffered saline (PBS, 
pH 7.2). Slides of cells were prepared by using a cytospin centrifuge (5 min, 500 rpm), 
dried in an air stream for 10 min, and fixed with ethanol/glacial acetic acid (20: 1 v/v) for 
15 min at -20°C. The slides were washed twice in PBS and incubated with 
FITC-labelled BSA preparation for 30 min at room temperature. The slides were then 
washed twice again, mounted in glycerol containing 10% PBS, and examined with a 
Leitt epifluorescence microscope. 
Hybrid cells from positive cultures were single-cell cloned and tested again by the 
same procedure. Positive subclones were selected and ascitic fluid was raised in BALB/c 
mice, as described, by the injection of hybridoma cells which had been washed five times 
with PBS.’ 
Characterization, purification and labeliing of anti-BSA antibody 
Immunoglobulin was purified from ascitic fluid by Thiophilic adsorption (T-gel) 
chromatography.’ The specificity of the monoclonal antibody for BSA was confirmed 
by Western blotting.8 IgG-isotype was determined using rabbit antisera with heavy- 
and light-chain specificities (Litton Bionetics Inc., Kensington, MD). Purified anti- 
BSA was labelled with horse-radish peroxidase (HRP, type IV, Sigma Chemical Co., 
St. Louis, MO), according to a modification” of the method previously described by 
Nakane et al. lo 
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Vaccines 
Commercial live veterinary virus vaccines were obtained from two different manu- 
facturers. The candidate live attenuated human rubella and measles vaccines had been 
produced in cell cultures (primary rabbit kidney cells and primary embryo chicken 
fibroblasts, respectively) by the RIVM. In-process sampling was done after washing 
and clarification of the bulk suspensions. 
Determination of BSA content by means of ELISA 
Serial dilutions of stock BSA preparations obtained from different commercial com- 
panies, HSA (HSA, CLB, Amsterdam, The Netherlands) and of sera from different 
animal species in 0.1 M phosphate buffer (pH 9-l) were used in 100 ~1 volumes to coat 
96-well, flat-bottomed polyvinylchloride ELISA plates (Flow Laboratories, Herts, 
UK). After incubation for 2 h at 37°C the plates were washed with tapwater containing 
0.05 % Tween SO (Merck-Schuchart , Darmstadt , FRG). To establish a dose-response 
curve, a 1:3000 dilution of HRP-labelled anti-BSA antibodies containing 0.25% 
ovalbumin (Grade III, Sigma) and 0.05% Tween 80 in 100 ~1 volumes was added and 
the plates were incubated for 1 h at room temperature. After washing the substrate, 
which consisted of 15 mg of tetramethylbenzidine (TMB, Sigma), 1.6 ml DMSO 
(Merck) and 10 ~1 30% H202 (in 100 ml of O-11 M sodium acetate buffer adjusted to 
pH 5.5 with saturated citric acid), was added. After 10 min, H$Od was added to a final 
concentration of 2 M to block the enzymatic reaction. The enzyme activity was 
determined by measuring the absorbance at 450 nm after 30 min on a Titertek reader 
(Flow Laboratories). The amount of BSA in vaccine preparations was determined in the 
same manner, but using vaccine instead of BSA solution. A dilution series of bovine 
serum protein ranging from O-48 txg ml-’ to 7.5 ng ml-’ was used as a standard. 
Samples were considered positive, and their BSA content estimated, if the mean 
absorbance values obtained were higher than the mean absorbance value obtained with 
6Ong of bovine serum protein per millilitre. 
Counter current electrophoresis for detecting BSA 
Counter current electrophoresis (CCE) was performed as described by Barme. I1 To 
measure the amount of bovine proteins, polyclonal rabbit anti-BSA serum was used at a 
I:4 dilution.* Serial dilutions to 7.5 ng ml-i of bovine serum protein were used as a 
reference. Virus vaccines were diluted serially and the amounts of BSA were determined 
by Coomassie blue staining. 
RESULTS 
Generation and selection of hybridomus 
The fusion of spleen cells from two BALB/c mice immunized with BSA and BALB/c 
myeloma cells yielded 11 hybridoma cell lines producing anti-BSA antibody as shown 
by IF using FITC conjugated BSA. One monoclonal antibody BS-16 (IgGi, K) was 
selected on the basis of its more than lOOO-fold higher reactivity with BSA than with 
HSA. Hybridoma B5-16 was cloned twice at limiting dilution and subsequently 
passaged as solid or ascitic tumours in BALB/c mice. The antibody was concentrated 
and affinity purified with T-gel. This monoclonal antibody preparation was found to 
have about the same reactivity with bovine, ovine and caprine serum albumin and more 
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than lOOO-fold lower reactivities with serum albumins from pig, dog, cat, rat, mouse 
and chicken as determined by using sera from these animals in the ELISA system. 
The specificity for BSA was confirmed by Western blotting. It reacted exclusively 
with a 68 Kd protein and not with other bovine serum proteins (not shown), 
Monoclonal antibody BS-16 was further used for the evaluation of its ability to test 
virus vaccines for BSA content in the ELISA system. 
Comparison of ELlSA and CCE 
For a comparison of ELISA and CCE as systems to detect BSA in virus vaccine 
preparations, 15 samples of human rubella vaccine collected in the process of 
production (RIVM) and 10 commercially available veterinary live virus vaccines were 
tested by both assays. 
TABLE 1. The determination of the BSA (ng ml- ’ of vaccine) content of 
human candidate vaccines by ELISA and CCE 
Vaccine samples ELISA CCE 
1 60 120 
2 60 60 
3 960 480 
4 60 30 
5 960 480 
6 60 60 
7 240 60 
8 60 60 
9 60 60 
10 60 60 
11 60 60 
12 240 120 
13 240 240 
14 240 120 
15 240 240 
TABLE 2. The determination of the BSA content (mg ml-‘) of 
veterinary vaccines by ELISA and CCE 
Vaccine samples ELISA CCE 
1 
2 
3 
4 
:, 
7 
8 
9 
10 
1.9 1.9 
2.4 1.9 
4.8 x lo-* 4.8 x lo-* 
1.2 0.5 
0.6 0.2 
0.6 0.1 
0.3 0.1 
2.4 0.5 
O-5 0.4 
0.6 0.2 
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The amounts of BSA found in the human vaccine preparations were 60-960 ng ml- ’ 
by ELISA and 30-480 ng ml-’ by CCE (Table 1). The amounts of BSA found in the 
veterinary vaccines ranged from 48 to 2400 pg ml- ’ by ELISA and from 48 to 1900 pg 
ml-’ by CCE (Table 2). The correlation coefficients (Y) between the results obtained 
with both methods were 0.95 for the human preparations and 0.77 for the veterinary 
vaccines. It can further be concluded that the ELISA is slightly more sensitive. 
It was not possible to measure the BSA content with this ELISA of human measles 
vaccine preparations to which a stabilizer with a relatively high concentration of HSA 
had been added. l2 This was due to a minor cross-reactivity of monoclonal antibody 
B5-16 with HSA. The testing of these preparations by CCE showed that the BSA 
contents were <6O ng ml. - ’ The addition of stabilizing buffers containing sorbitol or 
gelatin to vaccine preparations also rendered them unsuitable for determination of BSA 
by ELISA with monoclonal antibody B5-16 (not shown). 
Attempts to replace the polycloncal rabbit anti-serum by monocloncal antibody 
B5-16 in CCE were not successful due to the failure of the monoclonal antibody to 
precipitate BSA. 
DISCUSSION 
In order to develop an alternative to CCE for the measurement of the BSA content of 
virus vaccine preparations, we generated a monoclonal antibody directed against BSA 
which could be used in an ELISA system to measure the BSA content. Screening of the 
hybridomas was performed by a direct fluorescence method demonstrating antibodies 
in/on hybridoma cells because the presence of BSA in the hybridoma culture medium 
made it impossible to screen culture fluids for anti-BSA antibodies directly. Only one of 
the 11 monoclonal antibodies selected (BS- 16) was found to have a relatively high 
specificity for BSA (> lOOO-fold higher reactivity with BSA than with HSA), whereas 
the others showed high degrees of cross reactivities with HSA. The relatively low cross 
reactivity of this monoclonal antibody with HSA, however, still rendered it unsuitable 
for the measurement of the BSA contents of vaccine preparations to which HSA had 
been added as a stabilizer. Also the addition of other stabilizers such as sorbitol and 
gelatin interfered with the results of the ELISA with monoclonal antibody B5-16. The 
difference in correlations observed between CCE and ELISA for human and veterinary 
vaccines, respectively, may be related to the relatively low grade of purity of the latter. 
Apart from these drawbacks the relative simplicity and the possibility of testing large 
numbers ofsamples in a short time renders the ELISA an excellent tool for use in process 
control during vaccine production and for the testing of final products for their BSA 
content. Recently we have shown this ELISA to be suitable for monitoring the removal 
by immuno affinity chromatography l3 of bovine serum proteins in the purification of 
canine parvovirus. 
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